Postdoc position - Developing novel ways to control viruses for the targeted infection of cellular systems

This postdoctoral position is part of the Bio-Engineering Systems for Therapeutics (BEST) programme, a highly competitive initiative operated jointly by the Department of Biosystems Science and Engineering at ETH Zürich and Roche Pharma Research and Early Development (pRED). The project focuses on developing novel approaches to control viral vectors for targeted infection of cellular systems, with the aim of advancing gene therapy for genetic diseases. The research will investigate the thermodynamic and kinetic parameters that govern viral tropism, specifically the on/off rates of viral vectors binding to cell surface receptors. By applying multiparametric approaches, the project seeks to quantify and manipulate these interactions in cultured cells, organoids, tissues, and organs, ultimately enabling more precise control of viral infection and improving transduction efficiency. The position offers the opportunity to work independently on an interdisciplinary project at the highest scientific level, with access to facilities and expertise at both ETH Zürich and Roche in Basel. Co-supervision is provided by principal investigators from both institutions. The programme includes networking, career development support, regular seminars, and joint symposia. The fellowship is fully funded for an initial period of two years. Applicants should have a PhD in biology, biotechnology, biophysics, biomedicine, biomedical engineering, biochemistry, gene-based delivery methods, pharmacy, or related fields. Experience in cell biology, nanotechnology, gene therapy, and biophysics is advantageous. Candidates should demonstrate independence, teamwork, organizational skills, reliability, and a strong scientific track record, with fluency in English. ETH Zürich values diversity, sustainability, and an inclusive culture. Applications must be submitted online with all required documents as a single PDF. The deadline for applications is January 1, 2026, with evaluation on a rolling basis. For questions, contact Prof. Dr. Daniel J. Müller or Prof. Dr. Sascha Fauser. Administrative queries can be directed to the programme office.